Akebia Therapeutics (AKBA) Net Cash Flow Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -17.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.51% |
| Mar 31, 2026 | 12.83% |
| Dec 31, 2025 | 32.70% |
| Sep 30, 2025 | 222.60% |
| Jun 30, 2025 | 40.62% |
| Mar 31, 2025 | 33.57% |
| Dec 31, 2024 | 32.21% |
| Sep 30, 2024 | 48.38% |
| Jun 30, 2024 | 24.80% |
| Mar 31, 2024 | -26.84% |
| Dec 31, 2023 | -27.25% |
| Sep 30, 2023 | 54.61% |
| Jun 30, 2023 | -26.69% |
| Mar 31, 2023 | -1.55% |
| Dec 31, 2022 | -61.68% |
| Sep 30, 2022 | -71.00% |
| Jun 30, 2022 | -48.17% |
| Mar 31, 2022 | 37.79% |
| Dec 31, 2021 | -0.30% |
| Sep 30, 2021 | -231.12% |